The Medicines Company (NASDAQ:MDCO)

CAPS Rating: 4 out of 5

A pharmaceutical company provides innovative, cost effective acute care hospital products to the worldwide hospital marketplace.

Results 1 - 19 of 19

Recs

0
Member Avatar marsuculix (27.24) Submitted: 7/15/2014 4:04:09 AM : Outperform Start Price: $27.18 MDCO Score: -7.43

need for new antibiotics will support $MDCO ....

Recs

0
Member Avatar genedom (97.94) Submitted: 6/22/2014 12:37:48 PM : Outperform Start Price: $29.51 MDCO Score: -16.09

Still long way to go before the patent expired. The management is doing the right thing in filling the gap. Undervalued.

Recs

0
Member Avatar EvanBuck (99.82) Submitted: 9/2/2013 1:46:32 PM : Outperform Start Price: $26.06 MDCO Score: -50.98

zzlangerhans

Recs

0
Member Avatar TerryHoodSr (58.27) Submitted: 5/29/2013 2:41:47 PM : Outperform Start Price: $30.83 MDCO Score: -44.20

3yr rev growth 10%

Recs

3
Member Avatar zzlangerhans (99.85) Submitted: 5/26/2013 2:25:22 AM : Outperform Start Price: $33.82 MDCO Score: -44.55

I've watched Medicines' ascent from the sidelines but after reviewing the stock again this week I've decided to follow the story more closely with a green thumb. Angiomax revenues have remained solid, although I'm concerned regarding ongoing litigation with generic manufacturers. Regardless, the drug will only maintain exclusivity through 2019 due to agreements with Teva and Fresenius. However, the company has now produced a second act for the near term in the form of cangrelor, which recently showed strong superiority to Plavix in the CHAMPION PHOENIX trial. The company is also broadening their approach by inlicensing ALN-PCS RNAi from Alnylam and purchasing Incline Therapeutics and their Ionsys pain platform. I'm more skeptical about oritavancin, an antibiotic whose prospects failed to keep developer Targanta from being absorbed for a pittance. Nevertheless, positive phase III data from the SOLO-2 trial could give the stock a boost in mid 2013.

Recs

0
Member Avatar line70day (< 20) Submitted: 1/22/2013 10:12:49 AM : Outperform Start Price: $36.68 MDCO Score: -42.55

third Q rev increased 13.3% yr over yr to 136.8 M gasp net income decreased to $ 9.3M from compared$72.6M prior yr Q non gaap net income $ 21.8 M compared to $9.2M CEO sold shares and chief account sold shares

Recs

0
Member Avatar alizaidkhalid (< 20) Submitted: 1/21/2013 10:55:41 PM : Outperform Start Price: $30.15 MDCO Score: -51.96

because their product can be tolerated by large number of
people also drug very expensive in the market
although 96% of people suffer from poverty in my area but easy they can by MDCO product

Recs

0
Member Avatar HardnoseDotCom (71.14) Submitted: 4/25/2011 1:35:10 PM : Outperform Start Price: $16.17 MDCO Score: +8.55

low PEG, strong price uptrend

Recs

0
Member Avatar valuefocusgroup (21.34) Submitted: 4/5/2011 9:32:19 AM : Outperform Start Price: $16.31 MDCO Score: +6.48

Price/earnings of 8.28, market cap of 866.36, debt/equity of zero, Return on Invested Capital (TTM) of 35.00, based in New Jersey, United States, pharma company with focus on critical care patients.

Recs

0
Member Avatar ruinas (48.74) Submitted: 10/11/2010 11:16:44 AM : Outperform Start Price: $13.55 MDCO Score: +17.64

Improving profits in current environment plus recent FDA approval of new product.

Recs

0
Member Avatar Magnet0 (75.56) Submitted: 5/13/2009 5:50:39 PM : Outperform Start Price: $7.22 MDCO Score: +130.53

quality company, took a fatty nose dive

Recs

0
Member Avatar escarzamd (68.45) Submitted: 5/31/2008 2:26:29 PM : Outperform Start Price: $18.25 MDCO Score: -8.70

Hearing good things from cardiologists about Angiomax. recent support from journals. Could be a combo w/BMY for cath patients. No debt on board, so if this drug hits.......the stock could go out of the yard.

Recs

1
Member Avatar popsstocs (< 20) Submitted: 9/8/2007 3:39:10 PM : Outperform Start Price: $16.47 MDCO Score: +11.78

I have made some good profits off this CO.I guess it makes all that money from selling all those expensive medications,but what ever,It does me good and I played it again,and its already on its way to do ole pops right again.

Recs

0
Member Avatar StocksdatROCK (< 20) Submitted: 9/4/2007 7:53:25 PM : Outperform Start Price: $16.81 MDCO Score: +10.22

Has the worlds favorite item and to many customers

Recs

0
Member Avatar almond9090 (60.49) Submitted: 8/17/2007 5:43:16 AM : Outperform Start Price: $16.50 MDCO Score: +10.44

Consistent steady growth with well-established product should slightly outperform the market.

Recs

0
Member Avatar aaroger (89.99) Submitted: 7/27/2007 10:45:14 AM : Outperform Start Price: $17.21 MDCO Score: +6.51

34

Recs

1
Member Avatar agard43 (< 20) Submitted: 3/22/2007 10:31:33 PM : Underperform Start Price: $25.17 MDCO Score: +47.80

TheStreet.com: "There still seems to be a lot of hope built into the stock price. As Morgan Stanley analyst Stephen Herr wrote this week, "if the patent life is not extended, this stock looks broadly overvalued."

Recs

1
Member Avatar naygoo (53.06) Submitted: 12/11/2006 1:50:32 PM : Underperform Start Price: $30.96 MDCO Score: +69.87

Shares of the Medicines Co. (NASDAQ:MDCO - News) fell 10 percent on Monday after the U.S. Congress failed to enact a bill that would have helped the company's bid to extend a patent on its flagship drug Angiomax, a blood thinner.

Recs

0
Member Avatar walchak (< 20) Submitted: 8/26/2006 3:16:19 PM : Outperform Start Price: $22.00 MDCO Score: -50.48

their primary anticoagulant medicine is being used increasingly in the cardiology community for increased safety considerations and their next medicine in the pipeline may be even bigger

Results 1 - 19 of 19

Featured Broker Partners


Advertisement